CRISPR Therapeutics Statistics Share Statistics CRISPR Therapeutics has 90.95M
shares outstanding. The number of shares has increased by 1.4%
in one year.
Shares Outstanding 90.95M Shares Change (YoY) 1.4% Shares Change (QoQ) 0.69% Owned by Institutions (%) 74.67% Shares Floating 90.51M Failed to Deliver (FTD) Shares 35 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 22.07M, so 24.27% of the outstanding
shares have been sold short.
Short Interest 22.07M Short % of Shares Out 24.27% Short % of Float 27.41% Short Ratio (days to cover) 12.7
Valuation Ratios The PE ratio is -9.07 and the forward
PE ratio is -14.86.
CRISPR Therapeutics's PEG ratio is
-0.07.
PE Ratio -9.07 Forward PE -14.86 PS Ratio 94.87 Forward PS 36.9 PB Ratio 1.72 P/FCF Ratio -22.95 PEG Ratio -0.07
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for CRISPR Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 22.07,
with a Debt / Equity ratio of 0.12.
Current Ratio 22.07 Quick Ratio 22.07 Debt / Equity 0.12 Debt / EBITDA -0.5 Debt / FCF -1.55 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $89.06K Profits Per Employee $-931.94K Employee Count 393 Asset Turnover 0.02 Inventory Turnover n/a
Taxes Income Tax 3.59M Effective Tax Rate -0.99%
Stock Price Statistics The stock price has increased by 32.95% in the
last 52 weeks. The beta is 1.81, so CRISPR Therapeutics's
price volatility has been higher than the market average.
Beta 1.81 52-Week Price Change 32.95% 50-Day Moving Average 57.61 200-Day Moving Average 45.78 Relative Strength Index (RSI) 59.59 Average Volume (20 Days) 3,174,477
Income Statement In the last 12 months, CRISPR Therapeutics had revenue of 35M
and earned -366.25M
in profits. Earnings per share was -4.34.
Revenue 35M Gross Profit -75.25M Operating Income -466.57M Net Income -366.25M EBITDA -447.31M EBIT -466.57M Earnings Per Share (EPS) -4.34
Full Income Statement Balance Sheet The company has 298.26M in cash and 223.69M in
debt, giving a net cash position of 74.56M.
Cash & Cash Equivalents 298.26M Total Debt 223.69M Net Cash 74.56M Retained Earnings -1.37B Total Assets 2.03B Working Capital 1.63B
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -142.77M
and capital expenditures -1.9M, giving a free cash flow of -144.68M.
Operating Cash Flow -142.77M Capital Expenditures -1.9M Free Cash Flow -144.68M FCF Per Share -1.71
Full Cash Flow Statement Margins Gross margin is -215%, with operating and profit margins of -1333.05% and -1046.43%.
Gross Margin -215% Operating Margin -1333.05% Pretax Margin -1036.19% Profit Margin -1046.43% EBITDA Margin -1278.02% EBIT Margin -1333.05% FCF Margin -413.36%
